There is a pattern clinicians increasingly recognise: a woman in her forties whose systems have always just about held suddenly finds they do not. Focus goes. Organisation collapses. Emotional regulation gets harder. She is often told it is stress, or perimenopause, or that she is doing too much.
Sometimes two things are happening at once, and they are interacting.
The mechanism, in plain terms
ADHD involves dopamine signalling in the brain's executive networks. Oestrogen modulates dopamine — it influences how much is available and how effectively it is used.
During perimenopause, oestrogen does not decline smoothly. It fluctuates, sometimes wildly, before eventually settling low. If your executive function already runs on a narrower margin, removing a hormone that supports the underlying signalling has a disproportionate effect. Coping strategies that worked for thirty years stop working, and it feels sudden.
This is why some women describe perimenopause as the point their ADHD stopped being manageable — and why others are diagnosed for the first time in their forties, having compensated successfully until then.
What the research actually shows
This is an emerging area, and it is worth being straight about that. There is a good mechanistic rationale and a growing body of clinical description, but the treatment research is thin.
The 2025 review in Frontiers in Global Women's Health examines the interplay between hormonal fluctuation and ADHD across the female lifespan, and its conclusion is as much about the gap as the findings: hormonal transitions appear to exacerbate ADHD symptoms and mood disturbance, yet tailored treatment research is lacking.
A population-based cohort study on perimenopausal symptoms in women with and without ADHD found the ADHD group reported perimenopausal complaints at a substantially higher rate, with a large effect size — evidence that this is a real signal and not just clinical impression.
A 2026 review in Drugs & Aging looked specifically at pharmacological management of ADHD in women across perimenopause, menopause and post-menopause. That such a review is only appearing now tells you how new this is as a formal clinical question.
Why it gets missed
The symptom lists overlap almost completely. Brain fog, poor concentration, irritability, sleep disruption, emotional volatility — all appear in both. So whichever explanation a clinician reaches for first tends to absorb the whole picture.
If perimenopause is assumed, existing ADHD goes unrecognised. If ADHD is assumed, hormonal change goes unaddressed. Either way the woman gets partial treatment and concludes she is the problem.
What to raise with a GP
If this pattern sounds familiar, some things worth saying explicitly:
- Whether the difficulties are genuinely new, or long-standing ones that recently overwhelmed your coping systems. That distinction is diagnostically important.
- Whether symptoms fluctuate with your cycle. Cyclical worsening points toward a hormonal component.
- If you already have an ADHD diagnosis and take medication, that its effectiveness may change during perimenopause — this is reported clinically and is a reasonable thing to review.
Both conditions have their own NICE guidance — NG87 for ADHD, NG23 for menopause — and being assessed for one does not preclude the other.
Sources
- Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Frontiers in Global Women's Health, 2025. PubMed Central, PMC12277363.
- Perimenopausal symptoms in women with and without ADHD: a population-based cohort study. PubMed Central, PMC12538516.
- Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause. Drugs & Aging, 2026.
- National Institute for Health and Care Excellence. NICE guidelines NG87 (ADHD) and NG23 (Menopause).